Milestone Scientific (NYSE:MLSS) Now Covered by StockNews.com

Analysts at StockNews.com began coverage on shares of Milestone Scientific (NYSE:MLSS) in a research note issued to investors on Sunday. The firm set a “hold” rating on the stock.

Separately, Benchmark assumed coverage on Milestone Scientific in a research note on Thursday, October 10th. They set a “speculative buy” rating and a $1.25 price target on the stock.

Milestone Scientific Stock Up 5.2 %

Shares of Milestone Scientific stock opened at $0.76 on Friday. The firm has a market cap of $58.52 million, a price-to-earnings ratio of -10.83 and a beta of 1.08. Milestone Scientific has a twelve month low of $0.52 and a twelve month high of $1.10. The business has a 50-day moving average price of $0.89 and a 200-day moving average price of $0.83.

Milestone Scientific (NYSE:MLSS) last issued its quarterly earnings results on Thursday, August 15th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). The business had revenue of $1.85 million for the quarter. Milestone Scientific had a negative return on equity of 60.78% and a negative net margin of 54.87%.

Insiders Place Their Bets

In related news, Director Leonard Osser sold 107,984 shares of Milestone Scientific stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $0.93, for a total value of $100,425.12. Following the completion of the transaction, the director now directly owns 4,606,882 shares in the company, valued at approximately $4,284,400.26. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 251,106 shares of company stock valued at $236,451 over the last quarter. 24.75% of the stock is owned by insiders.

Milestone Scientific Company Profile

Milestone Scientific Inc, a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments.